Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ACIU 
AC Immune Ltd (ACIU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: ACIU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -33.83% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 194.80M USD | Price to earnings Ratio - | 1Y Target Price 9.31 |
Price to earnings Ratio - | 1Y Target Price 9.31 | ||
Volume (30-day avg) 119668 | Beta 1.58 | 52 Weeks Range 1.43 - 4.41 | Updated Date 06/18/2025 |
52 Weeks Range 1.43 - 4.41 | Updated Date 06/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.64 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -184.04% | Operating Margin (TTM) -1956.57% |
Management Effectiveness
Return on Assets (TTM) -17.07% | Return on Equity (TTM) -43.5% |
Valuation
Trailing PE - | Forward PE 11.24 | Enterprise Value 26259745 | Price to Sales(TTM) 7.03 |
Enterprise Value 26259745 | Price to Sales(TTM) 7.03 | ||
Enterprise Value to Revenue 0.76 | Enterprise Value to EBITDA -0.76 | Shares Outstanding 100410000 | Shares Floating 39872326 |
Shares Outstanding 100410000 | Shares Floating 39872326 | ||
Percent Insiders 38.01 | Percent Institutions 26.12 |
Analyst Ratings
Rating 4.75 | Target Price 9.25 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
AC Immune Ltd
Company Overview
History and Background
AC Immune SA is a Swiss-based clinical-stage biopharmaceutical company founded in 2003. It focuses on discovering, designing, and developing therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with misfolded proteins. The company has evolved from a research-driven entity to one with a pipeline of clinical-stage assets.
Core Business Areas
- Therapeutic Development: Development of immunotherapies and small molecules targeting amyloid beta, tau, and alpha-synuclein.
- Diagnostic Development: Development of diagnostic tools for early detection of neurodegenerative diseases.
- Licensing and Partnerships: Collaborations with pharmaceutical companies to advance and commercialize its pipeline.
Leadership and Structure
The leadership team comprises a CEO, CFO, CSO, and other key executives with experience in the pharmaceutical and biotechnology industries. The organizational structure is matrixed, with functional departments supporting product development teams.
Top Products and Market Share
Key Offerings
- ACI-24.060: An anti-Abeta active immunotherapy in Phase 2 clinical trials for Alzheimer's disease. Market share data unavailable as it is not yet commercialized. Competitors include Biogen (ADU), Eisai (LEQEMBI), and Eli Lilly (donanemab).
- Semorinemab (RO7105740): A humanized monoclonal antibody targeting tau protein, previously in Phase 2 trials for Alzheimer's disease in partnership with Roche. Development discontinued. Competitors include Prothena and AbbVie (Tau antibodies).
Market Dynamics
Industry Overview
The biopharmaceutical industry focusing on neurodegenerative diseases is characterized by high unmet medical needs, significant research and development investments, and regulatory challenges. The market is competitive, with numerous companies pursuing disease-modifying therapies.
Positioning
AC Immune is positioned as an innovative company focused on precision immunotherapies and diagnostics for neurodegenerative diseases, with a strong emphasis on targeting misfolded proteins. Its competitive advantage lies in its proprietary technology platforms and partnerships.
Total Addressable Market (TAM)
The TAM for Alzheimer's disease therapeutics is estimated to be in the tens of billions of dollars. AC Immune is positioned to capture a share of this market if its pipeline products are successful.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms
- Strong scientific expertise in misfolded proteins
- Strategic partnerships with pharmaceutical companies
- Diverse pipeline of therapeutic and diagnostic candidates
Weaknesses
- High dependence on clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
- High risk of clinical trial failure
- Semorinemab (RO7105740) - development discontinued
Opportunities
- Increasing prevalence of neurodegenerative diseases
- Advancements in biomarker technology for early diagnosis
- Potential for breakthrough therapies that modify disease progression
- Growing interest from pharmaceutical companies in partnering for Alzheimer's treatments.
Threats
- Regulatory hurdles and delays in approval
- Competition from established pharmaceutical companies
- Clinical trial failures
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- ESAI
Competitive Landscape
AC Immune faces significant competition from larger, more established pharmaceutical companies with greater financial resources and marketing capabilities. It differentiates itself through its innovative approach to targeting misfolded proteins and its strategic partnerships.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by progress in clinical trials and partnership agreements.
Future Projections: Future growth depends on the success of its pipeline programs, particularly ACI-24.060. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing its clinical programs, expanding its diagnostic capabilities, and seeking new partnerships.
Summary
AC Immune is a clinical-stage biopharmaceutical company focused on neurodegenerative diseases, primarily Alzheimer's. Their innovative approach to misfolded proteins and strategic partnerships are strengths. High dependence on clinical trial outcomes and competition from bigger companies are key challenges. Recent initiatives to advance clinical programs could drive growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Press Releases
- Analyst Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share estimates are approximate and based on available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AC Immune Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-09-23 | Co-Founder, CEO & Director Dr. Andrea Pfeifer Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 133 | Website https://www.acimmune.com |
Full time employees 133 | Website https://www.acimmune.com | ||
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.